Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.
2.

Serum γ-Glutamyltransferase as a Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide.

Takemura K, Ito M, Nakanishi Y, Kataoka M, Sakamoto K, Suzuki H, Tobisu KI, Koga F.

Anticancer Res. 2019 Oct;39(10):5773-5780. doi: 10.21873/anticanres.13780.

PMID:
31570481
3.

What are roles of multiparametric magnetic resonance imaging prior to transurethral resection of bladder tumor?

Koga F.

Transl Androl Urol. 2019 Aug;8(4):290-291. doi: 10.21037/tau.2019.07.21. No abstract available.

4.

Impact of fluorodeoxyglucose uptake on positron emission tomography/computed tomography on chemosensitivity and survival in patients with metastatic urothelial carcinoma.

Kobayashi M, Tanaka H, Tateishi U, Numao N, Yonese J, Ito M, Koga F, Fukushima H, Uehara S, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y.

Int J Urol. 2019 Aug;26(8):820-826. doi: 10.1111/iju.14022. Epub 2019 May 28.

PMID:
31140215
5.

Who Can Avoid Systematic Biopsy Without Missing Clinically Significant Prostate Cancer in Men Who Undergo Magnetic Resonance Imaging-Targeted Biopsy?

Nakanishi Y, Ito M, Fukushima H, Yokoyama M, Kataoka M, Ikuta S, Sakamoto K, Takemura K, Suzuki H, Tobisu KI, Koga F.

Clin Genitourin Cancer. 2019 Jun;17(3):e664-e671. doi: 10.1016/j.clgc.2019.03.011. Epub 2019 Mar 27.

PMID:
31003892
6.

Heat shock factor 1 (HSF1)-targeted anticancer therapeutics: overview of current preclinical progress.

Kijima T, Prince T, Neckers L, Koga F, Fujii Y.

Expert Opin Ther Targets. 2019 May;23(5):369-377. doi: 10.1080/14728222.2019.1602119. Epub 2019 Apr 7.

PMID:
30931649
7.

An Unusual Case of Acute Liver Failure Caused by Adjuvant Oral Tegafur-Uracil with Folinate Therapy for Colon Cancer Patient: a Case Report.

Hiraki M, Tanaka T, Koga F, Saito A, Oza N, Ikeda O, Manabe T, Miyoshi A, Kitahara K, Sato S, Noshiro H.

J Gastrointest Cancer. 2019 Mar 23. doi: 10.1007/s12029-019-00228-7. [Epub ahead of print] No abstract available.

PMID:
30903577
8.

Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients.

Kijima T, Tanaka H, Koga F, Masuda H, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y.

BJU Int. 2019 Aug;124(2):242-250. doi: 10.1111/bju.14736. Epub 2019 Apr 3.

PMID:
30811784
9.

Multifocal Synchronous Upper Urinary Tract Carcinosarcoma (Sarcomatoid Carcinoma) With Rhabdomyoblastic Differentiation.

Takemura K, Motoi T, Tonooka A, Funata N, Nakanishi Y, Kataoka M, Ito M, Sakamoto K, Suzuki H, Tobisu KI, Koga F.

Int J Surg Pathol. 2019 Aug;27(5):547-552. doi: 10.1177/1066896919828111. Epub 2019 Feb 15.

PMID:
30767589
10.

Metabolic and Molecular Basis of Sarcopenia: Implications in the Management of Urothelial Carcinoma.

Fukushima H, Fujii Y, Koga F.

Int J Mol Sci. 2019 Feb 11;20(3). pii: E760. doi: 10.3390/ijms20030760. Review.

11.

Asunaprevir and daclatasvir in hemodialysis patients with chronic hepatitis C virus genotype 1b infection.

Otsuka T, Kawaguchi Y, Mizuta T, Ide Y, Koga F, Kumagai T, Yoshioka W, Murayama K, Rikitake O, Ikeda Y, Ozaki I.

JGH Open. 2017 Nov 28;1(4):148-152. doi: 10.1002/jgh3.12026. eCollection 2017 Dec.

12.

Prognostic significance of serum γ-glutamyltransferase in patients with advanced urothelial carcinoma.

Takemura K, Fukushima H, Ito M, Kataoka M, Nakanishi Y, Sakamoto K, Suzuki H, Tobisu KI, Koga F.

Urol Oncol. 2019 Feb;37(2):108-115. doi: 10.1016/j.urolonc.2018.11.002. Epub 2018 Nov 24.

PMID:
30478012
13.

A Case of Renal Pelvic Cancer Complicated by Horseshoe Kidney Treated with RoboSurgeon Gasless Single-Port Retroperitoneoscopic Nephroureterectomy.

Suzuki H, Takemura K, Sakamoto K, Kataoka M, Ito M, Nakanishi Y, Tobisu KI, Koga F.

Case Rep Urol. 2018 Sep 18;2018:3231480. doi: 10.1155/2018/3231480. eCollection 2018.

14.

Impact of Sarcopenia as a Prognostic Biomarker of Bladder Cancer.

Fukushima H, Takemura K, Suzuki H, Koga F.

Int J Mol Sci. 2018 Oct 1;19(10). pii: E2999. doi: 10.3390/ijms19102999. Review.

15.

Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer.

Koga F, Takemura K, Fukushima H.

Int J Mol Sci. 2018 Sep 15;19(9). pii: E2777. doi: 10.3390/ijms19092777. Review.

16.

Evolution of Acquired Middle Ear Cholesteatoma in Patients With Ectrodactyly, Ectodermal Dysplasia, Cleft Lip/Palate (EEC) Syndrome.

Lourencone LFM, Koga FDT, Oliveira EB, Jorge JC, de Brito R.

Otol Neurotol. 2018 Sep;39(8):e679-e682. doi: 10.1097/MAO.0000000000001921.

PMID:
30113563
17.

Impact of Immunohistochemistry-Based Subtypes in Muscle-Invasive Bladder Cancer on Response to Chemoradiation Therapy.

Tanaka H, Yoshida S, Koga F, Toda K, Yoshimura R, Nakajima Y, Sugawara E, Akashi T, Waseda Y, Inoue M, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y.

Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1408-1416. doi: 10.1016/j.ijrobp.2018.06.030. Epub 2018 Jun 28.

PMID:
29960059
18.

[PRIMARY MALIGNANT MELANOMA OF THE FEMALE URETHRA: A CASE REPORT].

Suzuki H, Nakanishi Y, Yoshino K, Kataoka M, Fukushima H, Tobisu K, Koga F.

Nihon Hinyokika Gakkai Zasshi. 2018;109(2):111-115. doi: 10.5980/jpnjurol.109.111. Japanese.

19.

Preoperative chronic kidney disease is predictive of oncological outcome of radical cystectomy for bladder cancer.

Matsumoto A, Nakagawa T, Kanatani A, Ikeda M, Kawai T, Miyakawa J, Taguchi S, Naito A, Otsuka M, Nakanishi Y, Suzuki M, Koga F, Nagase Y, Kondo Y, Okaneya T, Tanaka Y, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y.

World J Urol. 2018 Feb;36(2):249-256. doi: 10.1007/s00345-017-2141-2. Epub 2017 Nov 28.

PMID:
29185045
20.

Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.

Fukushima H, Kataoka M, Nakanishi Y, Sakamoto K, Takemura K, Suzuki H, Ito M, Tobisu KI, Fujii Y, Koga F.

Urol Oncol. 2018 Apr;36(4):156.e9-156.e16. doi: 10.1016/j.urolonc.2017.09.016. Epub 2017 Oct 17.

PMID:
29051030
21.

Ureteral Involvement Is Associated with Poor Prognosis in Upper Urinary Tract Urothelial Carcinoma Patients Treated by Nephroureterectomy: A Multicenter Database Study.

Waseda Y, Saito K, Ishioka J, Matsuoka Y, Numao N, Fujii Y, Sakai Y, Koga F, Okuno T, Arisawa C, Kamata S, Nagahama K, Masuda H, Yonese J, Kageyama Y, Noro A, Tsujii T, Morimoto S, Gotoh S, Kihara K.

Eur Urol Focus. 2016 Aug;2(3):296-302. doi: 10.1016/j.euf.2015.10.008. Epub 2015 Nov 26.

PMID:
28723376
22.

Efficacy of radiotherapy for primary tumor in patients with unresectable pancreatic neuroendocrine tumors.

Iwata T, Ueno H, Itami J, Ito Y, Inaba K, Morizane C, Kondo S, Sakamoto Y, Shiba S, Sasaki M, Koga F, Okusaka T.

Jpn J Clin Oncol. 2017 Sep 1;47(9):826-831. doi: 10.1093/jjco/hyx081.

PMID:
28591817
23.

Autopsy case of systemic EBV-positive T-cell lymphoma of childhood with marked hepatomegaly in a middle-aged man.

Kai K, Koga F, Araki N, Shindo T, Eguchi Y, Toda S, Aishima S.

Pathol Int. 2017 Aug;67(8):431-433. doi: 10.1111/pin.12549. Epub 2017 Jun 1. No abstract available.

PMID:
28569394
24.

Standardization of the apparent diffusion coefficient value of bladder cancer across different centers: Applicability in predicting aggressive pathologic phenotypes.

Nishizawa T, Yoshida S, Koga F, Tanaka H, Kaga M, Watanabe K, Fukushima H, Nakanishi Y, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y, Kihara K.

Clin Imaging. 2017 Jul - Aug;44:121-126. doi: 10.1016/j.clinimag.2017.05.004. Epub 2017 May 5.

PMID:
28505504
25.

Impact of sarcopenia in the management of urological cancer patients.

Fukushima H, Koga F.

Expert Rev Anticancer Ther. 2017 May;17(5):455-466. doi: 10.1080/14737140.2017.1301209. Epub 2017 Mar 8. Review.

PMID:
28271727
26.

Epithelial-mesenchymal transition promotes SOX2 and NANOG expression in bladder cancer.

Migita T, Ueda A, Ohishi T, Hatano M, Seimiya H, Horiguchi SI, Koga F, Shibasaki F.

Lab Invest. 2017 Feb 27. doi: 10.1038/labinvest.2017.17. [Epub ahead of print]

27.

Retroperitoneal Teratoma in an Adult: A Potential Pitfall in the Differential Diagnosis of Adrenal Myelolipoma.

Kataoka M, Fukushima H, Nakanishi Y, Yokoyama M, Funata N, Motoi T, Tobisu KI, Koga F.

Case Rep Urol. 2016;2016:5141769. Epub 2016 Oct 20.

28.

Postoperative Changes in Skeletal Muscle Mass Predict Survival of Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy.

Fukushima H, Nakanishi Y, Kataoka M, Tobisu KI, Koga F.

Clin Genitourin Cancer. 2017 Apr;15(2):e229-e238. doi: 10.1016/j.clgc.2016.08.004. Epub 2016 Aug 10.

PMID:
27601279
29.

Editorial Comment to Stratified analysis of 800 Asian patients after robot-assisted radical prostatectomy with a median 64 months of follow up.

Koga F.

Int J Urol. 2016 Sep;23(9):774-5. doi: 10.1111/iju.13153. Epub 2016 Jul 8. No abstract available.

30.

Prognostic significance of sarcopenia in upper tract urothelial carcinoma patients treated with radical nephroureterectomy.

Fukushima H, Nakanishi Y, Kataoka M, Tobisu K, Koga F.

Cancer Med. 2016 Sep;5(9):2213-20. doi: 10.1002/cam4.795. Epub 2016 Jun 28.

31.

Prognostic significance of intensive local therapy to bone lesions in renal cell carcinoma patients with bone metastasis.

Fukushima H, Hozumi T, Goto T, Nihei K, Karasawa K, Nakanishi Y, Kataoka M, Tobisu K, Koga F.

Clin Exp Metastasis. 2016 Oct;33(7):699-705. doi: 10.1007/s10585-016-9805-y. Epub 2016 Jun 17.

PMID:
27316704
32.

Bladder Cancer Stem-Like Cells: Their Origin and Therapeutic Perspectives.

Ohishi T, Koga F, Migita T.

Int J Mol Sci. 2015 Dec 29;17(1). pii: E43. doi: 10.3390/ijms17010043. Review.

33.

Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients.

Shiba S, Morizane C, Hiraoka N, Sasaki M, Koga F, Sakamoto Y, Kondo S, Ueno H, Ikeda M, Yamada T, Shimada K, Kosuge T, Okusaka T.

Pancreatology. 2016 Jan-Feb;16(1):99-105. doi: 10.1016/j.pan.2015.11.001. Epub 2015 Nov 30.

PMID:
26718527
34.

Heat shock protein 90 targeting therapy: state of the art and future perspective.

Tatokoro M, Koga F, Yoshida S, Kihara K.

EXCLI J. 2015 Jan 6;14:48-58. doi: 10.17179/excli2015-586. eCollection 2015. Review.

35.

Anesthesia-Related and Perioperative Cardiac Arrest in Low- and High-Income Countries: A Systematic Review With Meta-Regression and Proportional Meta-Analysis.

Koga FA, El Dib R, Wakasugui W, Roça CT, Corrente JE, Braz MG, Braz JR, Braz LG.

Medicine (Baltimore). 2015 Sep;94(36):e1465. doi: 10.1097/MD.0000000000001465.

36.

Prognostic Significance of Sarcopenia in Patients with Metastatic Renal Cell Carcinoma.

Fukushima H, Nakanishi Y, Kataoka M, Tobisu K, Koga F.

J Urol. 2016 Jan;195(1):26-32. doi: 10.1016/j.juro.2015.08.071. Epub 2015 Aug 17.

PMID:
26292042
37.

High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol.

Tanabe K, Yoshida S, Koga F, Inoue M, Kobayashi S, Ishioka J, Tamura T, Sugawara E, Saito K, Akashi T, Fujii Y, Kihara K.

Clin Genitourin Cancer. 2015 Aug;13(4):e243-e251. doi: 10.1016/j.clgc.2015.03.002. Epub 2015 Mar 27.

PMID:
25936588
38.

[Adverse event and countermeasure with regard to FOLFIRINOX for pancreatic cancer].

Koga F, Ueno H, Morizane C, Kondo S, Sakamoto Y, Okusaka T.

Nihon Rinsho. 2015 Feb;73 Suppl 2:597-603. Japanese. No abstract available.

PMID:
25831830
39.

Editorial Comment to Prognostic significance of visceral obesity in patients with advanced renal cell carcinoma undergoing nephrectomy.

Fukushima H, Koga F.

Int J Urol. 2015 May;22(5):461-2. doi: 10.1111/iju.12731. Epub 2015 Feb 24. No abstract available.

40.

Sarcopenia as a prognostic biomarker of advanced urothelial carcinoma.

Fukushima H, Yokoyama M, Nakanishi Y, Tobisu K, Koga F.

PLoS One. 2015 Jan 22;10(1):e0115895. doi: 10.1371/journal.pone.0115895. eCollection 2015.

41.

Gasless laparoendoscopic single-port clampless sutureless partial nephrectomy for peripheral renal tumors: perioperative outcomes.

Kihara K, Koga F, Fujii Y, Masuda H, Tatokoro M, Yokoyama M, Matsuoka Y, Numao N, Ishioka J, Saito K.

Int J Urol. 2015 Apr;22(4):349-55. doi: 10.1111/iju.12687. Epub 2015 Jan 13.

42.

Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach.

Inoue M, Koga F, Yoshida S, Tamura T, Fujii Y, Ito E, Kihara K.

Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):303-11. doi: 10.1016/j.ijrobp.2014.05.043.

PMID:
25304790
43.

Bimodal pattern of the impact of body mass index on cancer-specific survival of upper urinary tract urothelial carcinoma patients.

Ishioka J, Masuda H, Kijima T, Tatokoro M, Yoshida S, Yokoyama M, Matsuoka Y, Numao N, Koga F, Saito K, Fujii Y, Sakai Y, Arisawa C, Okuno T, Nagahama K, Kamata S, Yonese J, Kageyama Y, Noro A, Morimoto S, Tsujii T, Kitahara S, Gotoh S, Kihara K.

Anticancer Res. 2014 Oct;34(10):5683-8.

PMID:
25275074
44.

Candidate selection for quadrant-based focal ablation through a combination of diffusion-weighted magnetic resonance imaging and prostate biopsy.

Matsuoka Y, Numao N, Saito K, Tanaka H, Kumagai J, Yoshida S, Ishioka J, Koga F, Masuda H, Kawakami S, Fujii Y, Kihara K.

BJU Int. 2016 Jan;117(1):94-101. doi: 10.1111/bju.12901. Epub 2015 May 24.

45.

Diffusion-weighted MRI as a potential imaging biomarker reflecting the metastatic potential of upper urinary tract cancer.

Uchida Y, Yoshida S, Kobayashi S, Koga F, Ishioka J, Satoh S, Ishii C, Tanaka H, Matsuoka Y, Numao N, Saito K, Masuda H, Fujii Y, Kihara K.

Br J Radiol. 2014 Oct;87(1042):20130791. doi: 10.1259/bjr.20130791. Epub 2014 Jul 30.

46.

Role of diffusion-weighted magnetic resonance imaging as an imaging biomarker of urothelial carcinoma.

Yoshida S, Koga F, Masuda H, Fujii Y, Kihara K.

Int J Urol. 2014 Dec;21(12):1190-200. doi: 10.1111/iju.12587. Epub 2014 Jul 30. Review.

47.

Equivalent survival and improved preservation of renal function after distal ureterectomy compared with nephroureterectomy in patients with urothelial carcinoma of the distal ureter: a propensity score-matched multicenter study.

Fukushima H, Saito K, Ishioka J, Matsuoka Y, Numao N, Koga F, Masuda H, Fujii Y, Sakai Y, Arisawa C, Okuno T, Yonese J, Kamata S, Nagahama K, Noro A, Morimoto S, Tsujii T, Kitahara S, Gotoh S, Higashi Y, Kihara K.

Int J Urol. 2014 Nov;21(11):1098-104. doi: 10.1111/iju.12554. Epub 2014 Jul 14.

48.

Diffusion-weighted magnetic resonance imaging in management of bladder cancer, particularly with multimodal bladder-sparing strategy.

Yoshida S, Koga F, Kobayashi S, Tanaka H, Satoh S, Fujii Y, Kihara K.

World J Radiol. 2014 Jun 28;6(6):344-54. doi: 10.4329/wjr.v6.i6.344. Review.

49.

Pre-operative risk stratification for cancer-specific survival in patients with renal cell carcinoma with venous involvement who underwent nephrectomy.

Nakayama T, Saito K, Fujii Y, Abe-Suzuki S, Nakanishi Y, Kijima T, Yoshida S, Ishioka J, Matsuoka Y, Numao N, Koga F, Kihara K.

Jpn J Clin Oncol. 2014 Aug;44(8):756-61. doi: 10.1093/jjco/hyu072. Epub 2014 May 28.

PMID:
24872404
50.

Bone abnormal signal incidentally found in pre-biopsy diffusion-weighted MRI for suspected prostate cancer: what does it reflect?

Yachida Y, Yoshida S, Takeshita H, Sawamura C, Tanaka H, Satoh S, Uchida Y, Ishioka J, Matsuoka Y, Numao N, Koga F, Saito K, Fujii Y, Kihara K.

Urol Int. 2014;93(2):170-5. doi: 10.1159/000356999. Epub 2014 Apr 9.

PMID:
24732031

Supplemental Content

Support Center